NCT02149420View on ClinicalTrials.gov

PD of VAY736 in Patients With Primary Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 23, 2014

Primary Completion Date

February 7, 2018

Study Completion Date

February 7, 2018

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

VAY736

DRUG

Placebo

Trial Locations (1)

10117

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY